Pazopanib is a first-generation targeted drug

Pazopanib (Pazopanib) is an oral second-generation multi-target tyrosine kinase inhibitor. It is a second-generation targeted therapy drug that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor and c-kit, which are key proteins responsible for tumor growth and survival. Pazopanib exhibits promising potency against all human VEGFRs and closely related tyrosine receptor kinases in vitro and antitumor activity in several human tumor xenografts, including renal cell carcinoma (RCC) as well as soft tissue sarcomas. In Phase I and II clinical trials, pazopanib was generally well tolerated, with the main side effects being hypertension, fatigue, or gastrointestinal disturbances.